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Background: Anosognosia is a common manifestation of Alzheimer’s disease. There is an association
between impaired awareness and frontal-executive cognitive deficits. Anosognosia is also correlated with
decreased metabolism in the right hemisphere, particularly in frontal lobe regions.
Objective: To investigate pathological correlates of anosognosia in Alzheimer’s disease.
Design: 41 subjects followed longitudinally in the University of Pittsburgh memory disorders clinic and with
necropsy verified Alzheimer’s disease were divided into two groups, based on previous clinical
assessment: +Aware (n = 23) and 2Aware (n = 18). A subset analysis matching subjects for dementia
severity using mini-mental state examination scores was also carried out (13 +Aware; 13 2Aware).
Histopathological data from necropsy brain tissue consisted of senile plaque (SP) and neurofibrillary tangle
(NFT) counts (regional density) from four different brain regions in the right and left hemispheres: superior
and middle frontal gyri (SMF), superior temporal isocortex (ST), the prosubiculum of the hippocampus
(PRO), and the entorhinal cortex (EC).
Results: SP density was greater in the right PRO region of 2Aware subjects (F = 6.54, p = 0.015) than
+Aware subjects. Significant differences between SP or NFT density were not observed in any other
regions. In the subset analysis matching for dementia severity, SP density was again greater in the right
PRO region of 2Aware subjects than in the other regions (F = 12.72, p = 0.002).
Conclusions: Increased SP density in the right PRO region suggests that selective pathological involvement
of this area contributes to awareness deficits in Alzheimer’s disease. The putative role of the PRO in self
appraisal may reflect its interconnections with other medial temporal and prefrontal regions.
A
lzheimer’s disease has many neuropsychiatric mani-
festations and one of the more clinically significant and
common of these is lack of awareness of neurological
deficits, or anosognosia. Several studies have investigated
clinical, neuropsychological, and functional imaging data in
an attempt to localise anosognosia to specific regions or
circuits in the brain. In one such study, by Lopez et al,1
anosognosia was determined by questioning the subject and
an informant about awareness of deficits, as well as by
observing the subject’s state after completing a mental status
examination. The results indicated greater deficits in frontal
functions or ‘‘central executive system’’ functioning in
Alzheimer’s disease subjects with anosognosia. Michon et al
used neuropsychological data, most notably the Wisconsin
card sorting test, and found that the degree of anosognosia
was correlated with executive or frontal lobe dysfunction in
Alzheimer’s disease.2 Ott et al noted a typical failure of self
monitoring in early Alzheimer’s disease, as well as a
correlation of awareness of deficits with performance on
executive and visuospatial function tests.3
Among several studies of anosognosia in Alzheimer’s
disease reported by Starkstein and colleagues,4–7 one invol-
ving single photon emission computed tomography (SPECT)
imaging showed that anosognosia was associated with
decreased regional cerebral blood flow in the right hemi-
sphere, particularly in prefrontal (dorsolateral and orbito-
frontal) areas.7 In another SPECT study, Reed et al found that
anosognosia in Alzheimer’s disease was correlated with right
dorsolateral frontal lobe (frontal superior area) perfusion
deficits.8 Ott and colleagues9 showed that lack of insight in
Alzheimer’s disease was associated with right temporo-
occipital region hypoperfusion. Together, these studies
impute a relation between anosognosia in Alzheimer’s
disease and right hemisphere dysfunction, principally invol-
ving frontal and temporal regions.
To our knowledge, there have not been any clinicopatho-
logical studies of anosognosia in Alzheimer’s disease. In the
current study we examined senile plaque (SP) and neuro-
fibrillary tangle (NFT) counts, used as correlates of disease
burden, from frontal and temporal lobe regions in both
hemispheres to investigate possible neuropathological sub-
strates of anosognosia in Alzheimer’s disease. Based on
previous clinical and neuroimaging studies, we hypothesised
that one or more of the right hemisphere regions would have
a significantly greater SP or NFT burden, or both, in
Alzheimer’s disease subjects with impaired awareness of
deficits than in subjects with relatively preserved awareness.
METHODS
Study population
Subject selection criteria included necropsy verified
Alzheimer’s disease and the exclusion of other significant
and potentially confounding pathological diagnoses such as
other neurodegenerative diseases and dementias (subjects
with vascular dementia were specifically excluded). The
subjects had been followed longitudinally in the University of
Pittsburgh Alzheimer’s Disease Research Center (ADRC)
memory disorders clinic. All subjects had one or more
comprehensive assessments, including an evaluation by a
neurologist of the subject’s degree of awareness (assessment
of performance) after completion of neuropsychological
testing. Among 224 subjects with neuropathological data
who were initially reviewed, 104 with Alzheimer’s disease
(excluding other significant pathological concomitants) and
complete neuropathological data were identified. A subse-
quent review of the clinical data yielded 41 subjects with both
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neuropathological and clinical data who died between 1987
and 1992. Subjects were matched for sex, age, duration of
symptoms, and interval between the last examination and
death (table 1).
Clinical data
After the standard ADRC evaluation, which included a
comprehensive mental status examination, subjects were
classified with respect to demonstrable awareness of their
own cognitive deficits by the examining clinician on an
informal semiquantitative scale:
1. Spontaneous complaint.
2. Agrees when questioned.
3. Unaware.
4. Denies but appears aware.
This rating was based on information obtained during a
clinical interview by the examiner in conjunction with formal
neuropsychological testing. For purposes of the current study,
subjects were divided into +Aware (without anosognosia,
categories 1 and 2), and 2Aware (with anosognosia,
categories 3 and 4). Ratings used for analyses were those
from the last clinical visit before death. Of 41 subjects, 23
were +Aware and 18 were 2Aware. As dementia severity,
based on mini-mental state examination (MMSE)10 scores,
was significantly greater in 2Aware subjects, a subset of 26
subjects was matched for dementia severity (13 +Aware and
13 2Aware, table 1) to eliminate this potential confounder.
Neuropathological data
Brain removal, dissection, tissue sampling, fixation, process-
ing, staining, and SP and NFT counting using Bielschowsky
stain have been described previously.11 12 SP and NFT counts
were done by two neuropathologists separately, and a third
neuropathologist verified the Alzheimer’s disease diagnosis
and resolved differences in the counts. Senile plaque counts
included both neuritic and diffuse plaques, and the neuro-
pathological diagnosis of Alzheimer’s disease was based on
Khachaturian criteria,13 which were the prevailing criteria at
the time of pathological examination. Although more recent
NIA-Reagan criteria14 include probabilistic diagnostic criteria
based on NFT and SP counts, virtually all subjects included in
this study would meet criteria for ‘‘intermediate’’ or ‘‘high’’
probability of Alzheimer’s disease.
Five microscopic fields were counted between cortical
layers II and IV of the different brain regions at a
magnification of 6200, and the mean SP and NFT counts
were calculated for each region. Neuropathological raters
were blind to awareness group. Pearson correlation coeffi-
cients for repeated rater and inter-rater reliability for both
counts were high (for SP counts, 0.94 and 0.97, respectively;
for NFT counts, 0.87 and 0.91, respectively).12 Counts were
obtained from the following right and left brain regions:
superior and middle frontal gyri (SMF), superior temporal
isocortex (ST), prosubiculum of the hippocampus (PRO), and
entorhinal cortex (EC). The regions selected for analysis were
based on previous unrelated neuropathological studies11 12
and therefore do not necessarily represent a comprehensive
assessment for pathological substrates of anosognosia.
Analysis of variance (ANOVA) was used to compare SP and
NFT counts in left and right homologous regions to test the
hypothesis that 2Aware subjects would have greater SP and/
or NFT burden in right frontal and temporal regions than
+Aware subjects.
RESULTS
In the initial group of 41 subjects analysed (+Aware, n=23;
2Aware, n=18), SP density was significantly greater only in
the right PRO region of2Aware subjects (F=6.54, p=0.015;
table 2). Comparison of the other regions in each hemisphere
showed no differences between +Aware and2Aware subjects
on SP, NFT, or combined SP+NFT density. A x2 analysis for
sex by group showed no significant difference.
In the subset analysis of 26 subjects (+Aware, n=13;
2Aware, n=13) matched for dementia severity using MMSE
scores, SP density was again significantly greater in the right
PRO region of 2Aware subjects than in +Aware subjects
(F=12.72; p=0.002). SP density also showed a borderline
significant trend towards being higher in the left PRO region
of 2Aware subjects compared with + Aware subjects
(F=4.23, p=0.051). No differences in NFT density or
combined SP+NFT density were observed in any other region
between +Aware and 2Aware subjects in this derivative
sample. After Bonferroni correction for multiple comparisons
(four regions 6 two sides 6 two measures), the finding of
increased SP density in the right PRO region remained
significant (p=0.032).
DISCUSSION
Using necropsy data from a retrospective case series, we
examined a hypothesis based on clinical studies that
anosognosia in subjects with Alzheimer’s disease would be
associated with greater pathological involvement of right
frontal or temporal regions. The principal finding of greater
SP density in the right prosubiculum region, which was
statistically robust after controlling for dementia severity and
multiple comparisons, is consistent with the main study
hypothesis and is to our knowledge the first report of a
neuropathological correlate of anosognosia in Alzheimer’s
disease. Although this retrospective study must be considered
preliminary, owing to various methodological limitations, it
provides insight into the putative anatomical substrates of
impaired awareness in Alzheimer’s disease.
Anatomically, the PRO region of the hippocampal forma-
tion was originally recognised by Lorente de Nó15 as the
Table 1 Sex, age, duration of symptoms, interval between last examination and death,
and mini-mental state examination score in subjects with and without anosognosia




interval (years) MMSE score
+Aware (n = 23) 11/12 79 (8) 8 (5) 2 (1) 14 (7)
2Aware (n = 18) 11/7 76 (9) 7 (4) 2 (1) 9 (7)
+Aware (n = 13)* 6/7 79 (9) 8 (3) 2 (1) 10 (3)
2Aware (n = 13)* 7/6 77 (9) 7 (3) 2 (1) 9 (4)
Values are mean (SD) except sex.
*Subset of subjects matched for dementia severity.
MMSE score significantly different (p,0.03).
F, female; M, male; MMSE, mini-mental state examination; +Aware, without anosognosia; 2Aware, with
anosognosia.
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transition zone between the subiculum and the adjacent CA1
region of the hippocampus (fig 1). This nomenclature has not
been universally accepted, in part because the PRO region is
not well developed in rodents. The phylogenetic trend
towards a more differentiated zone of transitional cortex
between the CA1 and subicular regions of the hippocampal
formation may augur a role for the PRO in integrative
cognitive processes such as gnosis.
Hyman and colleagues16 drew attention to the prosubicu-
lum as being one of the subregions of the hippocampal
formation consistently bearing the greatest burden of plaque
and tangle pathology in Alzheimer’s disease. Anatomically,
the prosubiculum is a primary source of hippocampal
formation efferents from the intrinsic perforant pathway
originating in layer II of the entorhinal cortex to the
amygdala (particularly the accessory basal nucleus) and to
layer IV of the entorhinal cortex (fig 2). Both the entorhinal
cortex and the prosubiculum receive reciprocal projections
from the amygdala, which has been postulated to play a
functional role in conscious awareness.17 The connectivity of
the amygdala suggests that information regarding emotional
valence supporting awareness may be conveyed to the
hippocampal formation primarily at the input and output
zones of its intrinsic circuitry. The presence of feedback
projections from the prosubiculum to layer IV of the
entorhinal cortex, which is typically less severely involved
than layer II in Alzheimer’s disease, suggest that pathological
involvement of the deeper layers of the entorhinal cortex may
Table 2 Senile plaque and neurofibrillary tangle counts in four brain regions
+Aware (n = 23) 2Aware (n = 18) +Aware (n = 13)* 2Aware (n = 13)*
SMF R SP 23 (19) 21 (13) 20 (11) 22 (14)
R NFT 6 (7) 8 (7) 7 (6) 7 (6)
L SP 22 (17) 20 (12) 19 (11) 22 (13)
L NFT 7 (7) 9 (8) 9 (7) 9 (9)
ST R SP 20 (17) 17 (12) 18 (8) 15 (9)
R NFT 9 (10) 11 (10) 10 (9) 10 (10)
L SP 22 (21) 23 (22) 20 (16) 25 (25)
L NFT 9 (9) 12 (10) 10 (9) 11 (10)
PRO R SP 7 (4) 11 (6) 6 (4)` 12 (4)`
R NFT 19 (16) 24 (15) 22 (19) 28 (14)
L SP 9 (4) 12 (6) 8 (4)1 12 (6)1
L NFT 23 (17) 28 (16) 25 (20) 33 (15)
EC R SP 16 (9) 17 (10) 16 (11) 16 (11)
R NFT 15 (8) 16 (9) 15 (8) 15 (9)
L SP 15 (11) 15 (10) 16 (14) 12 (7)
L NFT 15 (8) 16 (8) 15 (8) 16 (7)
Values are means (SD).
*Subset matched for dementia severity.
p =0.015; `p =0.002; 1p=0.051.
EC, entorhinal cortex; L, left; NFT, neurofibrillary tangle; PRO, prosubiculum of the hippocampus; R, right; SMF,
superior and middle frontal gyri; ST, superior temporal isocortex; SP, senile plaque; +Aware, without anosognosia;
2Aware, with anosognosia.
Figure 1 Transverse section through the hippocampus and adjacent
regions. CA1, CA2, CA3, CA4, regions of the hippocampus; DG,
dentate gyrus; EC, entorhinal cortex; F, fimbria; PRO, prosubiculum; S,
subiculum; TH, temporal horn of the lateral ventricle. Magnification68.
Figure 2 Principal connections of the prosubiculum. Pathways on the
right side of the figure include feedback projections from the
prosubiculum (PRO) to the entorhinal cortex (EC), and output to
diencephalic structures (MB, mammillary body; ANT, anterior nucleus of
the thalamus) that are implicated in episodic memory. The left side of the
figure depicts connections from the PRO to the amygdala (AMG) and
anterior cingulate (AC) that are putatively implicated in self awareness.
MTT, mammilothalamic tract; PP, perforant pathway, the unidirectional
trisynaptic pathway that constitutes the primary intrinsic circuitry of the
hippocampal formation; PRC, perirhinal cortex.
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play a role in mediating the observed relation between
anosognosia and dementia severity.
Other features of the prosubiculum that support a putative
role in self directed awareness are dense reciprocal connec-
tions with the anterior cingulate,18 which has been implicated
in error detection,19 self reflection,20 and awareness of one’s
actions,21 and its dense cholinergic innervation.22 Emerging
data support a prominent role of acetylcholine in mediating
conscious awareness,23 and we have reported preliminary
findings that increased awareness of personally and envir-
onmentally relevant information is among the most consis-
tent effects of cholinesterase inhibitor treatment in patients
with Alzheimer’s disease.24 25 Our findings from this study are
consistent with a cholinergic component of impaired deficit
awareness, as senile plaque density has been reported to be
much more robustly correlated with loss of cholinergic
markers in Alzheimer’s disease than NFT density.12
Although we did not observe any histopathological differ-
ences between +Aware and 2Aware subjects in the medial
frontal cortex, this region is noteworthy for having a more
variable relation between cholinergic deficits and histopatho-
logical burden in Alzheimer’s disease.26 It is possible that
disproportionately severe cholinergic deficits in this area may
contribute to altered awareness in Alzheimer’s disease.
The current study has several limitations. First, awareness
was clinically assessed at an earlier time point before death
(on average, two years before death and pathological
evaluation) and was based on a derived categorical measure.
The lag interval between clinical assessment and death is a
common problem in clinicopathological correlation studies
and might be addressed by in vivo functional imaging
techniques that offer real time correlative data. Although
functional brain imaging methods have relatively limited
spatial resolution compared with pathological assessment,
they offer the potential advantage of being able to assess
functional connectivity patterns associated with neural net-
works involved in generating and modulating different
components of awareness. Prospective studies using a
validated and graded assessment of awareness would provide
a more robust approach to investigating pathological corre-
lates of anosognosia in Alzheimer’s disease. This point
underscores the variable manifestations of anosognosia in
this condition and the need to specify with more precision the
nature of the awareness deficit.27
Second, although senile plaque counts included both
diffuse and neuritic plaques, the fact that all subjects had
clinical dementia in the absence of other relevant patholo-
gical substrates suggests that Alzheimer’s disease was the
principal cause of the dementia. Potential subjects with
evidence of other pathological lesions were rigorously
excluded from this study for the sake of homogeneity.
Future studies using more contemporary pathological criteria
(NIA-Reagan), modern immunostaining methods, and quan-
titative stereological techniques would enhance clinicopatho-
logical correlation studies.
Third, a relatively limited number of brain regions was
assessed, based on tissue availability from this retrospective
sample. Different components of anosognosia (for example,
awareness of deficit v concern about deficit) may have
overlapping but distinctive pathological correlates that could
not be examined in this study. Although our findings suggest
that amyloid plaque burden in the right prosubiculum region
is associated with impaired awareness in Alzheimer’s disease,
awareness is not an ‘‘all or nothing’’ phenomenon and entails
multiple component processes and substrates. Among the
few 2Aware individuals who had right prosubiculum senile
plaque counts below the group mean, the counts tended to be
higher in either the right prefrontal (SMF) or temporal (ST)
regions. This observation suggests that lesions of the right
prosubiculum are a common, though not invariable, correlate
of anosognosia in Alzheimer’s disease, and that awareness is
probably mediated by distributed neural networks. Future
studies should include examination of the amygdala, as well
as other prefrontal and parietal cortical and subcortical
(thalamus) regions, to evaluate possible histopathological
differences in other candidate regions that may contribute to
anosognosia in Alzheimer’s disease.
One of the more intriguing clinical aspects of anosognosia
in Alzheimer’s disease is its variability. In a cross sectional
study of 350 patients with this disorder (MMSE range 5 to
27), 18% had no insight into their cognitive deficits, 15% had
preserved insight, and the rest had partial awareness of their
cognitive deficits.28 A recent study by Santillan and collea-
gues29 observed a similar distribution of anosognosia in
subjects with Alzheimer’s disease, and found that impaired
insight was an independent predictor of functional decline.
Another recent study30 reported apathy to be more strongly
associated with anosognosia in subjects with Alzheimer’s
disease than executive cognitive deficits. Although impaired
deficit awareness could be a predisposing factor to greater
risk taking behaviour and poor judgment, there is remarkably
little information on the natural history and clinical
consequences of anosognosia in Alzheimer’s disease. Future
studies should also address these areas of inquiry, particu-
larly in the earliest disease stages.
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